Enlivex Selected to Present at Israeli BioMed 2025 Conference
Enlivex Therapeutics (NASDAQ: ENLV) has been selected to present at the Israeli BioMed 2025 Conference in Tel Aviv from May 21-23, 2025. The presentation, titled "Enlivex—Harnessing the Natural Healing Power of Macrophages to Treat Inflammatory Diseases," will focus on their cell therapy product Allocetra™.
Allocetra™ is a universal, off-the-shelf cell therapy designed to reset macrophages to their homeostatic state. The company is currently conducting multiple Phase I/II trials, with promising interim results in moderate knee osteoarthritis showing significant improvements including:
- 47% reduction in pain
- 46% improvement in joint function
- 40% decrease in stiffness
Additional trial readouts are expected in 2025.
Enlivex Therapeutics (NASDAQ: ENLV) è stata selezionata per presentare al Israeli BioMed 2025 Conference a Tel Aviv dal 21 al 23 maggio 2025. La presentazione, intitolata "Enlivex—Sfruttare il potere naturale di guarigione dei macrofagi per trattare le malattie infiammatorie", si concentrerà sul loro prodotto di terapia cellulare Allocetra™.
Allocetra™ è una terapia cellulare universale, pronta all’uso, progettata per riportare i macrofagi al loro stato omeostatico. L’azienda sta attualmente conducendo diversi studi di Fase I/II, con risultati intermedi promettenti nell’osteoartrite moderata del ginocchio che mostrano miglioramenti significativi tra cui:
- Riduzione del dolore del 47%
- Miglioramento della funzione articolare del 46%
- Diminuzione della rigidità del 40%
Sono previsti ulteriori risultati degli studi nel 2025.
Enlivex Therapeutics (NASDAQ: ENLV) ha sido seleccionada para presentar en la Conferencia Israeli BioMed 2025 en Tel Aviv del 21 al 23 de mayo de 2025. La presentación, titulada "Enlivex—Aprovechando el poder natural de curación de los macrófagos para tratar enfermedades inflamatorias", se centrará en su producto de terapia celular Allocetra™.
Allocetra™ es una terapia celular universal y lista para usar, diseñada para restablecer los macrófagos a su estado homeostático. La compañía está actualmente llevando a cabo múltiples ensayos de Fase I/II, con resultados interinos prometedores en osteoartritis moderada de rodilla que muestran mejoras significativas incluyendo:
- Reducción del dolor del 47%
- Mejora del funcionamiento articular del 46%
- Disminución de la rigidez del 40%
Se esperan más resultados de los ensayos en 2025.
Enlivex Therapeutics (NASDAQ: ENLV)는 2025년 5월 21일부터 23일까지 텔아비브에서 열리는 Israeli BioMed 2025 컨퍼런스에서 발표자로 선정되었습니다. "Enlivex—염증성 질환 치료를 위한 대식세포의 자연 치유력 활용"이라는 제목의 발표는 그들의 세포 치료제 Allocetra™에 초점을 맞출 예정입니다.
Allocetra™는 대식세포를 항상성 상태로 재설정하도록 설계된 범용 즉시 사용 가능한 세포 치료제입니다. 회사는 현재 여러 단계 I/II 임상시험을 진행 중이며, 중등도 무릎 골관절염에서 유망한 중간 결과를 보이며 유의미한 개선을 나타내고 있습니다:
- 통증 47% 감소
- 관절 기능 46% 향상
- 경직 40% 감소
추가 임상 결과는 2025년에 발표될 예정입니다.
Enlivex Therapeutics (NASDAQ : ENLV) a été sélectionnée pour présenter lors de la Conférence Israeli BioMed 2025 à Tel Aviv du 21 au 23 mai 2025. La présentation, intitulée « Enlivex – Exploiter le pouvoir naturel de guérison des macrophages pour traiter les maladies inflammatoires », portera sur leur produit de thérapie cellulaire Allocetra™.
Allocetra™ est une thérapie cellulaire universelle, prête à l’emploi, conçue pour réinitialiser les macrophages à leur état homéostatique. La société mène actuellement plusieurs essais de phase I/II, avec des résultats intermédiaires prometteurs dans l’arthrose modérée du genou montrant des améliorations significatives telles que :
- Réduction de la douleur de 47 %
- Amélioration de la fonction articulaire de 46 %
- Diminution de la raideur de 40 %
D’autres résultats d’essais sont attendus en 2025.
Enlivex Therapeutics (NASDAQ: ENLV) wurde ausgewählt, auf der Israeli BioMed 2025 Konferenz in Tel Aviv vom 21. bis 23. Mai 2025 zu präsentieren. Die Präsentation mit dem Titel „Enlivex – Nutzung der natürlichen Heilkräfte von Makrophagen zur Behandlung entzündlicher Erkrankungen“ wird sich auf ihr Zelltherapieprodukt Allocetra™ konzentrieren.
Allocetra™ ist eine universelle, sofort verfügbare Zelltherapie, die darauf ausgelegt ist, Makrophagen in ihren homöostatischen Zustand zurückzuversetzen. Das Unternehmen führt derzeit mehrere Phase I/II-Studien durch, mit vielversprechenden Zwischenergebnissen bei moderater Kniearthrose, die signifikante Verbesserungen zeigen, darunter:
- 47 % Schmerzlinderung
- 46 % Verbesserung der Gelenkfunktion
- 40 % Verringerung der Steifheit
Weitere Studienergebnisse werden für 2025 erwartet.
- None.
- None.
Presentation to highlight Allocetra™ and the therapeutic potential of macrophage reprogramming in inflammatory diseases
Ness-Ziona, Israel, May 20, 2025 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. (Nasdaq: ENLV, the “Company”), a clinical-stage macrophage reprogramming immunotherapy company, today announced that the Company has been selected to present at the upcoming Israeli BioMed 2025 Conference, taking place May 21–23, 2025 in Tel Aviv, Israel. The Company’s presentation is titled “Enlivex—Harnessing the Natural Healing Power of Macrophages to Treat Inflammatory Diseases” and will be delivered by the Company’s CEO on May 21st as part of the session “Personalized Pathways; Genetic and Cellular Based Therapies for Rare and Complex Diseases”.
Allocetra™, Enlivex’s universal, off-the-shelf cell therapy, is designed to reset macrophages—key immune cells—to their homeostatic, or “balanced,” state. Non-homeostatic macrophages are implicated in a broad range of chronic and life-threatening diseases, and Allocetra™’s unique reprogramming capability may offer a promising strategy for immune system rebalancing and disease resolution.
Enlivex is currently advancing a broad clinical pipeline with Allocetra™, including multiple Phase I/II trials in osteoarthritis and psoriatic arthritis. Recent data from a six-month interim readout in moderate knee osteoarthritis showed statistically significant reductions in pain (
ABOUT ENLIVEX
Enlivex is a clinical stage macrophage reprogramming immunotherapy company developing Allocetra™, a universal, off-the-shelf cell therapy designed to reprogram macrophages into their homeostatic state. Resetting non-homeostatic macrophages into their homeostatic state is critical for immune system rebalancing and resolution of life-threatening and life debilitating conditions. For more information, visit http://www.enlivex.com.
Safe Harbor Statement: This press release contains forward-looking statements, which may be identified by words such as “expects,” “plans,” “projects,” “will,” “may,” “anticipates,” “believes,” “should,” “would”, “could,” “intends,” “estimates,” “suggests,” “has the potential to” and other words of similar meaning, including statements regarding expected cash balances, market opportunities for the results of current clinical studies and preclinical experiments, the effectiveness of, and market opportunities for, ALLOCETRA TM programs. All such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Investors are cautioned that forward-looking statements involve risks and uncertainties that may affect Enlivex’s business and prospects, including the risks that Enlivex may not succeed in generating any revenues or developing any commercial products; that the products in development may fail, may not achieve the expected results or effectiveness and/or may not generate data that would support the approval or marketing of these products for the indications being studied or for other indications; that ongoing studies may not continue to show substantial or any activity; and other risks and uncertainties that may cause results to differ materially from those set forth in the forward-looking statements. The results of clinical trials in humans may produce results that differ significantly from the results of clinical and other trials in animals. The results of early-stage trials may differ significantly from the results of more developed, later-stage trials. The development of any products using the ALLOCETRA TM product line could also be affected by a number of other factors, including unexpected safety, efficacy or manufacturing issues, additional time requirements for data analyses and decision making, the impact of pharmaceutical industry regulation, the impact of competitive products and pricing and the impact of patents and other proprietary rights held by competitors and other third parties. In addition to the risk factors described above, investors should consider the economic, competitive, governmental, technological and other factors discussed in Enlivex’s filings with the Securities and Exchange Commission, including in the Company’s most recent Annual Report on Form 20-F filed with the Securities and Exchange Commission. The forward-looking statements contained in this press release speak only as of the date the statements were made, and we do not undertake any obligation to update forward-looking statements, except as required under applicable law.
Contact:
Dave Gentry, CEO
RedChip Companies, Inc.
1-407-644-4256
ENLV@redchip.com
FAQ
What is Allocetra™ and how does it work?
What are the latest clinical results for ENLV's Allocetra™ in osteoarthritis?
What clinical trials is Enlivex (ENLV) currently conducting?
When and where is Enlivex presenting at the Israeli BioMed 2025 Conference?
